Alcon AG vs Arqit Quantum Inc — how do they compare? Alcon AG trades at $72.82 (market cap $36.44B), while Arqit Quantum Inc trades at $23.74 (market cap $424.79M). The key difference: Alcon AG is far larger — about 85.8× Arqit Quantum Inc's market cap, and Alcon AG pays a 0.48% dividend while Arqit Quantum Inc pays none. Which is the better fit depends on your goals.
| ALC | ARQQ | |
|---|---|---|
Market Cap | $36.44B | $424.79M |
Sector | Health | Technology |
52-Week High | $90.12 | $58.27 |
52-Week Low | $62.02 | $11.78 |
Enterprise Value | $40.28B | $398.10M |
Dividend Yield | 0.48% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.63, up 2.53% today, with a bullish technical signal from moving averages and strong recent earnings beats. Revenue growth is steady, reaching $10.40B in 2025, though net income margin dipped to 5.92%. Positive news includes raised 2026 profit guidance and new product launches driving investor optimism.
The outlook is positive with a consensus price target of $86.67 implying 17.7% upside, supported by analyst buy ratings. Risks include elevated P/E of 57.52 and potential tariff impacts, but operational cash flow strength and strategic collaborations provide a solid foundation for growth.
ARQQ trades at $24.10, up 6.59% today, with a bullish technical signal from moving averages. The company shows explosive revenue growth (829% YoY in H1 2026) but remains deeply unprofitable with a -4,508% net margin. Recent news highlights quantum-safe encryption partnerships with telecom and government clients, driving investor optimism despite significant financial losses.
Outlook remains speculative with high risk/reward profile. The quantum security market offers substantial growth potential, but ARQQ must demonstrate path to profitability amid heavy operating losses. Analyst consensus is divided (50% Buy, 50% Hold), reflecting uncertainty about timeline for sustainable operations.
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →